Drugs / 300 IR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00803244 | Jan → Aug 2009 | — | Stallergenes Greer | Completed | Missed primary |
| Phase 3 | NCT00955825 | Oct 2008 → Aug 2009 | seasonal allergic rhinitis | Stallergenes Greer | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Stallergenes Greer | Results Stallergenes Greer will present new evidence on long-term outcomes in allergen immunotherapy at EAACI 2026 stallergenesgreer.com ↗
YOBI met its primary endpoint, demonstrating a statistically significant and clinically meaningful 41% improvement in the ARC total combined score during the second pollen season versus placebo (p<0.0001, between-group difference of -2.62 points). |
| 2021-05-31 | Stallergenes Greer | Regulatory Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet stallergenesgreer.com ↗
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite (HDM) allergen immunotherapy tablet Actair®. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Stallergenes Greer | Stallergenes Greer will present new evidence on long-term outcomes in allergen immunotherapy at EAACI 2026 stallergenesgreer.com ↗ |
| 2021-05-31 | Stallergenes Greer | Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet stallergenesgreer.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 300 IR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00955825 ↗ |
| Route | Other | “sublingual tablets” NCT00803244 ↗ |